NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

McNamara, Mairéad G.; Swain, Jayne; Craig, Zoe; Sharma, Rohini; Faluyi, Olusola Olusesan; Wadsley, Jonathan; Morgan, Clare; Wall, Lucy; Chau, Ian; Reed, Nick; Sarker, Debashis; Margetts, Jane; Krell, Daniel; Cave, Judith; Sothi, Sharmila; Anthoney, Alan; Bell, Christopher; Patel, Anand; Oughton, Jamie B.; Cairns, David A.; Mansoor, Wasat; Lamarca, Ángela; Valle, Juan W.

doi:10.1016/j.eclinm.2023.102015

Cited by 6 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ORR was 11.1% in arm A and 10.3% in arm B, with similar median PFS (3 months and 2 months) and OS (6 months and 6 months) in patients receiving nal-IRI plus 5-fluorouracil and docetaxel, respectively. According to the authors, 5-fluorouracil plus nal-IRI may represent a viable therapeutic option in this setting, whereas the poor performance of docetaxel, with the poor associated tolerability profile, should discourage further investigation of this regimen in this setting [ 59 ]. Another recent phase II trial aimed at evaluating the activity of temozolomide monotherapy in patients with extrapulmonary NECs progressing on first-line platinum–etoposide treatment.…”

Section: Therapeutic Approach To Upo-nenmentioning

confidence: 99%

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Corti,

Rossi,

Cafaro

et al. 2024

Cancers

View full text Add to dashboard Cite

Among neuroendocrine neoplasms (NENs), a non-negligible proportion (9–22%) is represented by sufferers of NENs of unknown primary origin (UPO), a poor prognostic group with largely unmet clinical needs. In the absence of standard therapeutic algorithms, current guidelines suggest that the treatment of UPO-NENs should be based on tumor clinical-pathological characteristics, disease burden, and patient conditions. Chemotherapy represents the backbone for the treatment of high-grade poorly differentiated UPO-NENs, usually providing deep but short-lasting responses. Conversely, the spectrum of available systemic therapy options for well-differentiated UPO-NENs may range from somatostatin analogs in indolent low-grade tumors, to peptide receptor radioligand therapy, tyrosine kinase inhibitors (TKIs), or chemotherapy for more aggressive tumors or in case of high disease burden. In recent years, molecular profiling has provided deep insights into the molecular landscape of UPO-NENs, with both diagnostic and therapeutic implications. Although preliminary, interesting activity data have been provided about upfront chemoimmunotherapy, the use of immune checkpoint inhibitors (ICIs), and the combination of ICIs plus TKIs in this setting. Here, we review the literature from the last 30 years to examine the available evidence about the treatment of UPO-NENs, with a particular focus on future perspectives, including the expanding scenario of targeted agents in this setting.

show abstract

Section: Therapeutic Approach To Upo-nenmentioning

confidence: 99%

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Corti,

Rossi,

Cafaro

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Several drugs and regimens, such as dacarbazine, topotecan, liposomial irinotecan + 5-fluorouracil, docetaxel, and the addition of bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), to FOLFIRI, failed to prove beneficial in GEP-NEC patients [46][47][48][49]. Nevertheless, the SENECA study, a randomized phase II trial of CAPTEM vs. FOLFIRI in lung and GEP-NECs, completed enrollment and the results are awaited soon (NCT03387592) [50].…”

Section: Management Of Gep-necsmentioning

confidence: 99%

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Stumpo,

Formelli,

Persano

et al. 2023

JCM

View full text Add to dashboard Cite

Neuroendocrine carcinomas (NECs) are poorly differentiated and highly aggressive epithelial neuroendocrine neoplasms. The most common primary site is the lung, but they may arise in every organ. Approximately 37% of extrapulmonary NECs (EP-NECs) occur in the gastroenteropancreatic (GEP) tract, followed by the genitourinary (GU) system and gynecological tract. As a result of their rarity, there is scant evidence to guide treatment recommendations, and a multidisciplinary approach is essential for the management of such patients. Platinum-based chemotherapy currently represents the standard of care for EP-NECs of any site, mirroring the management of small-cell lung cancer (SCLC), but further approaches are still under investigation. Indeed, ongoing trials evaluating targeted therapies, immune checkpoint inhibitors (ICIs), and radionuclide therapy could provide potentially breakthrough therapeutic options. Given the relative dearth of evidence-based literature on these orphan diseases, the aim of this review is to provide an overview of the pathology and current treatment options, as well as to shed light on the most pressing unmet needs in the field.

show abstract

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial

Zhang,

Shi,

et al. 2024

European Journal of Cancer

View full text Add to dashboard Cite

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Cited by 6 publications

References 37 publications

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial

Contact Info

Product

Resources

About